GLSI 10-Q: SEC filing

Greenwich LifeSciences

Filed with the SEC on · accession 0001493152-26-052438

GLSI filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. Greenwich LifeSciences filed its Q3 2026 10-Q quarterly report, reporting no revenue and continued net losses typical of a clinical-stage biopharmaceutical company.

Summary of the filing

Greenwich LifeSciences filed its Q3 2026 10-Q quarterly report, reporting no revenue and continued net losses typical of a clinical-stage biopharmaceutical company. The company remains focused on developing its GP2 immunotherapy product candidate.

Key details

FilerGreenwich LifeSciences, Inc.
Licensing partnerThe Henry M. Jackson Foundation

✦ Ask GOAX AI about this filing — what it means for GLSI, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for GLSI?

Click here

Frequently asked questions

What did GLSI file with the SEC on Nov 16, 2026?

GLSI filed a 10-Q (SEC filing). Greenwich LifeSciences filed its Q3 2026 10-Q quarterly report, reporting no revenue and continued net losses typical of a clinical-stage biopharmaceutical company. The company remains focused on developing its GP2 immunotherapy product candidate.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other GLSI SEC filings

Get alerts when GLSI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days